Research Analysts Issue Forecasts for PetMed Express, Inc.’s Q3 2018 Earnings (PETS)

PetMed Express, Inc. (NASDAQ:PETS) – Equities research analysts at Northcoast Research increased their Q3 2018 earnings per share estimates for PetMed Express in a research note issued to investors on Tuesday. Northcoast Research analyst E. Snyder now forecasts that the company will earn $0.32 per share for the quarter, up from their prior estimate of $0.30. Northcoast Research currently has a “Buy” rating and a $54.00 target price on the stock. Northcoast Research also issued estimates for PetMed Express’ FY2018 earnings at $1.60 EPS, Q1 2019 earnings at $0.49 EPS, Q2 2019 earnings at $0.42 EPS, Q3 2019 earnings at $0.34 EPS, Q4 2019 earnings at $0.41 EPS and FY2019 earnings at $1.66 EPS.

PetMed Express (NASDAQ:PETS) last posted its quarterly earnings data on Monday, October 23rd. The company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.30 by $0.13. PetMed Express had a net margin of 11.58% and a return on equity of 31.46%. The company had revenue of $66.70 million for the quarter, compared to the consensus estimate of $63.41 million. During the same quarter in the previous year, the firm posted $0.24 EPS. The business’s revenue was up 9.7% compared to the same quarter last year.

TRADEMARK VIOLATION NOTICE: “Research Analysts Issue Forecasts for PetMed Express, Inc.’s Q3 2018 Earnings (PETS)” was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this news story can be accessed at https://stocknewstimes.com/2017/11/19/research-analysts-issue-forecasts-for-petmed-express-inc-s-q3-2018-earnings-pets.html.

Other research analysts also recently issued research reports about the stock. ValuEngine upgraded shares of PetMed Express from a “hold” rating to a “buy” rating in a report on Friday, September 1st. Sidoti upgraded shares of PetMed Express from a “neutral” rating to a “buy” rating and set a $47.00 target price on the stock in a research report on Thursday, August 24th. BidaskClub lowered shares of PetMed Express from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 22nd. Zacks Investment Research lowered shares of PetMed Express from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 25th. Finally, Craig Hallum reiterated a “hold” rating and set a $40.00 target price (down from $43.00) on shares of PetMed Express in a research report on Monday, August 21st. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the company’s stock. PetMed Express presently has an average rating of “Hold” and an average target price of $42.00.

PetMed Express (PETS) opened at $38.67 on Friday. PetMed Express has a twelve month low of $19.21 and a twelve month high of $50.90. The stock has a market cap of $796.76, a PE ratio of 25.95, a PEG ratio of 2.32 and a beta of 1.09.

The firm also recently announced a quarterly dividend, which was paid on Friday, November 17th. Stockholders of record on Monday, November 6th were given a dividend of $0.20 per share. The ex-dividend date was Friday, November 3rd. This represents a $0.80 annualized dividend and a dividend yield of 2.07%. PetMed Express’s dividend payout ratio (DPR) is currently 53.69%.

In other news, Director Ronald J. Korn sold 1,000 shares of PetMed Express stock in a transaction dated Friday, October 27th. The shares were sold at an average price of $35.57, for a total transaction of $35,570.00. Following the sale, the director now directly owns 73,833 shares in the company, valued at approximately $2,626,239.81. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 4.00% of the stock is currently owned by insiders.

A number of large investors have recently added to or reduced their stakes in the business. Acrospire Investment Management LLC acquired a new position in PetMed Express in the second quarter valued at about $110,000. Pinebridge Investments L.P. boosted its position in PetMed Express by 1.0% in the second quarter. Pinebridge Investments L.P. now owns 2,704 shares of the company’s stock valued at $110,000 after buying an additional 27 shares in the last quarter. Sei Investments Co. boosted its position in PetMed Express by 50,142.9% in the third quarter. Sei Investments Co. now owns 3,517 shares of the company’s stock valued at $117,000 after buying an additional 3,510 shares in the last quarter. Thompson Siegel & Walmsley LLC acquired a new position in PetMed Express in the third quarter valued at about $149,000. Finally, Fred Alger Management Inc. acquired a new position in PetMed Express in the second quarter valued at about $162,000. Hedge funds and other institutional investors own 87.13% of the company’s stock.

PetMed Express Company Profile

PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.

Earnings History and Estimates for PetMed Express (NASDAQ:PETS)

Receive News & Ratings for PetMed Express Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetMed Express Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply